Get the latest news, insights, and market updates on HROW (Harrow, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
A Look At Harrow (HROW) Valuation After Mixed Q4 Results And 2026 Profitability Concerns
Why Harrow stock is back in focus after its latest results Harrow (HROW) has been in the spotlight after Q4 2025 results combined strong revenue growth with an earnings miss, a back end loaded 2026 outlook, and planned spending on a larger sales force. See our latest analysis for Harrow. Harrow's latest earnings miss and back end loaded 2026 guidance have hit sentiment in the short term, with a 7 day share price return of 33.01% decline and year to date share price return of 27.53% decline,... Mar 6, 2026 - $HROW
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:40 AM ET, in Miami, Florida. The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event. About HarrowHarrow, In Mar 4, 2026 - $HROW
Harrow Q4 Earnings Call Highlights
Harrow (NASDAQ:HROW) executives used the company’s fourth-quarter 2025 earnings call to highlight what CEO Mark Baum described as a five-year transformation into a diversified ophthalmic platform, while outlining a 2026 plan that includes expanded commercial investment, two product launches, and con Mar 3, 2026 - $HROW
Harrow (HROW) Q4 2025 Earnings Call Transcript
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow Health, Inc.'s control, including risks and uncertainties described from time to time in its SEC filings, such as the risks and uncertainties related to the company's ability to make commercially available its FDA-approved products and compounded formulations and technologies and FDA approval of certain drug candidates in a timely manner or at all. Harrow Health, Inc.'s results may differ materially from those projected. Harrow Health, Inc. disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. Mar 3, 2026 - $HROW
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to support a planned Phase 3 clinical trial evaluating TRIESENCE (preservative-free triamcinolone acetonide injectable suspension) 40 mg/mL for the treatment of ocular inflammation and pain following cataract surgery. The Mar 3, 2026 - $HROW
Harrow: Q4 Earnings Snapshot
NASHVILLE, Tenn. AP) — Harrow, Inc. HROW) on Monday reported fourth-quarter earnings of $6.6 million. Mar 2, 2026 - $HROW
Harrow (HROW) Misses Q4 Earnings Estimates
Harrow (HROW) delivered earnings and revenue surprises of -34.46% and +0.33%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Mar 2, 2026 - $HROW
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple